Spero Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2013-01-01
- Employees
- 46
- Market Cap
- $74.5M
- Introduction
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company was founded by Ankit A. M...
Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease
- Conditions
- Interventions
- First Posted Date
- 2020-09-17
- Last Posted Date
- 2022-02-28
- Lead Sponsor
- Spero Therapeutics
- Target Recruit Count
- 2
- Registration Number
- NCT04553406
- Locations
- 🇺🇸
Medical Facility, Pittsburgh, Pennsylvania, United States
Bioequivalence Study Comparing Two Tablet Formulations of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects
- Conditions
- Interventions
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2020-08-12
- Lead Sponsor
- Spero Therapeutics
- Target Recruit Count
- 36
- Registration Number
- NCT04421885
- Locations
- 🇺🇸
Medical Facility, Tempe, Arizona, United States
Effect of Tebipenem on Normal Human Intestinal Microbiota
- Conditions
- Interventions
- First Posted Date
- 2020-05-06
- Last Posted Date
- 2021-05-04
- Lead Sponsor
- Spero Therapeutics
- Target Recruit Count
- 30
- Registration Number
- NCT04376554
- Locations
- 🇸🇪
Karolinska University Hospital, Huddinge, Stockholm, Sweden
Study to Examine the Effect of Antacid and Omeprazole on the Single-Dose Pharmacokinetics of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects
- First Posted Date
- 2020-04-30
- Last Posted Date
- 2020-09-04
- Lead Sponsor
- Spero Therapeutics
- Target Recruit Count
- 20
- Registration Number
- NCT04368585
- Locations
- 🇺🇸
Medical Facility, Phoenix, Arizona, United States
A Single-Dose, Randomized, Placebo- and Active-Control, Four-Way, Cross-Over Study for the Evaluation of the Effect of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) on the QT/QTc Intervals in Adult Healthy Subjects
- First Posted Date
- 2020-01-23
- Last Posted Date
- 2020-03-13
- Lead Sponsor
- Spero Therapeutics
- Target Recruit Count
- 24
- Registration Number
- NCT04238195
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
Phase 1 Study of PK and Safety of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Subjects With Various Degrees Of Renal Function
- Conditions
- Interventions
- First Posted Date
- 2019-11-26
- Last Posted Date
- 2020-11-27
- Lead Sponsor
- Spero Therapeutics
- Target Recruit Count
- 39
- Registration Number
- NCT04178577
- Locations
- 🇺🇸
Medical Facility, Orlando, Florida, United States
A Study of the Safety, Tolerability, and Pharmacokinetics of SPR720 in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2019-01-08
- Last Posted Date
- 2019-10-28
- Lead Sponsor
- Spero Therapeutics
- Target Recruit Count
- 96
- Registration Number
- NCT03796910
- Locations
- 🇬🇧
Simbec Research, Ltd., Merthyr Tydfil,, Mid Glamorgan, United Kingdom
A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of SPR206 in Healthy Volunteers
- First Posted Date
- 2019-01-03
- Last Posted Date
- 2020-01-10
- Lead Sponsor
- Spero Therapeutics
- Target Recruit Count
- 94
- Registration Number
- NCT03792308
- Locations
- 🇦🇺
Scientia Clinical Research Ltd., Randwick, New South Wales, Australia
Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
- Conditions
- Interventions
- First Posted Date
- 2018-12-28
- Last Posted Date
- 2022-07-25
- Lead Sponsor
- Spero Therapeutics
- Target Recruit Count
- 1372
- Registration Number
- NCT03788967
- Locations
- 🇷🇺
Medical facility, Saint Petersburg, Russian Federation
🇺🇦Medical Facility, Zhytomyr, Ukraine
Phase 1 Study of Safety, Tolerability and Pharmacokinetics of SPR994
- Conditions
- Interventions
- First Posted Date
- 2018-01-10
- Last Posted Date
- 2018-08-28
- Lead Sponsor
- Spero Therapeutics
- Target Recruit Count
- 124
- Registration Number
- NCT03395249
- Locations
- 🇦🇺
Scientia Clinical Research Ltd, Randwick, New South Wales, Australia